Navigation Links
Pinnacle Biologics and INTERmedic Medical Devices announce strategic manufacturing and distribution agreement for cancer laser technology

BANNOCKBURN, Ill., June 26, 2012 /PRNewswire/ -- Pinnacle Biologics, Inc., a bio-pharmaceutical technology company developing and manufacturing novel therapies for oncology and rare diseases and European-based INTERmedic, a medical laser and light technology company, announced a global manufacturing and distribution agreement of INTERmedic's latest photodynamic therapy (PDT) laser for exclusive use with Pinnacle's PHOTOFRIN ® (porfimer sodium) for injection. 

PDT is a two-step process, which uses a photosensitizing drug activated inside the body by laser light to kill cells. The agreement creates a customized PDT application combining PHOTOFRIN, a photoactivated agent, with INTERmedic's newest endoscopic laser delivery device. The device is already approved in Europe. Pinnacle anticipates registration in the United States and other global markets within the next 12-18 months.

"PDT is an impactful, yet under utilized treatment strategy," said Guillermo Herrera, Pinnacle Executive Chairman and CEO. "Pinnacle's goal is to support worldwide development of PDT with PHOTOFRIN in a way that elevates awareness and use among physicians and alerts patients to this cancer treatment option."

Pinnacle acquired PHOTOFRIN in March 2011 with the goal of solidifying its corporate presence and global leadership in the photodynamic therapy field by normalizing product supply, expanding availability and education among current customers, and targeting areas of unmet medical need as new indications for use of PDT.

Pinnacle is working with regulators, top academic institutions and opinion leaders to accelerate product development in areas where the product has shown evidence of safety and efficacy for the benefit of patients affected by rare and devastating diseases.

"PDT for cancer is an advanced therapeutic approach that needs to be expanded and further developed," said Patrick Ross, MD, Ph.D., professor of clinical surgery and Chairman of Pinnacle's Scientific Advisory Board. "Pinnacle's strategic development of PDT with PHOTOFRIN and its commitment to extending its indications and applications are clear signals we can achieve those goals."

About Photodynamic therapy (PDT) and PHOTOFRIN

Photodynamic therapy with PHOTOFRIN is a two-stage process requiring administration of both drug and light. The first stage of PDT is the intravenous injection of PHOTOFRIN. The second stage of therapy uses illumination with non-burning laser light 40–50 hours following injection with PHOTOFRIN. When injected, PHOTOFRIN is attracted to certain tissues, especially cancer cells. Tumor destruction results from biochemical reactions, not heat.  Tumor selectivity occurs through a combination of preferential retention of PHOTOFRIN by the tumor and selective delivery of light to the tumor site.

PHOTOFRIN is FDA approved for the treatment of non-small cell lung cancer (NSCLC) and esophageal cancer. The product is available in the USA, several major European countries, Japan, several Latin American and Southeast Asian markets. PHOTOFRIN also is approved for high-grade dysplasia (HGD) in Barrett's esophagus (BE) in North America. It also has Orphan Drug Designation (ODD) for cholangio-carcinoma and as adjuvant therapy to surgery for the treatment of malignant pleural mesothelioma.

For additional information about PHOTOFRIN, please see full prescribing information available at

About Pinnacle

Pinnacle Biologics, Inc. is a privately held bio-pharmaceutical company specializing in revitalizing healthcare therapies to expand therapeutic potential and maximize favorable patient outcomes. The company is headquartered in Bannockburn, Illinois. Its European subsidiary, Pinnacle BiologicsBV, is headquartered in Amsterdam and is the holder of the European Marketing Authorizations for Pinnacle products.

About INTERmedic

INTERmedic is a dynamic laser & light technology company in a flux of constant expansion. The company is dedicated to the development, production and marketing of innovative laser and highly advanced pulsed light systems as well as other new technologies covering a wide range of medical applications. INTERmedic is one of Europe's leading laser manufacturers and marketers.

INTERmedic offers attending physicians innovative, patient-friendly solutions, well adapted to use by the applicant in aesthetics, dermatology, vascular medicine, plastic and general surgery. The company's solid standing in vascular surgery, with the minimally invasive method to treat varicose veins, guarantees its position as the world's number one in endovenous laser treatments.

SOURCE Pinnacle Biologics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. CMC Biologics Achieves Successful Pre-Approval European GMP Inspection by MHRA for Commercial Manufacturing
2. Chinese Compulsory Immunization Program for Livestock Creates Massive Opportunity for Animal Vaccines and Biologics Developers
3. Avaxia Biologics Announces Appointment of Michael D. Rivard as VP Corporate Development
4. CSL Behring Announces FDA Filing of Biologics License Application for 4-Factor PCC for Urgent Reversal of Vitamin K Antagonist Anticoagulant Therapy
5. Avaxia Biologics is Awarded U.S. Patent for Method to Treat Radiation Damage to the Digestive Tract and Mucositis Caused by Radiation
6. Synthetic Biologics Appoints Carol Reed, M.D., as Senior Vice President of Clinical & Regulatory Affairs
7. Althea Technologies Appoints Dr. Kristin DeFife, Director, Biologics Manufacturing And Jack Wright, VP, Sales and Marketing
8. ICON Medical Imaging Selects AG Mednet to Give Clinical Trial Sponsors Zero-Delay Efficiency and Faster Decision-Making Results
9. US Disposable Medical Supplies Market
10. Accuray and Erasmus Medical Center Sign Master Research and Collaboration Agreement
11. Collagen Matrix Celebrates 15th Anniversary in the Medical Device Business
Post Your Comments:
(Date:6/26/2016)... Ontario , June 27, 2016  VMS Rehab ... Company,s Board will take whatever measures required to build ... Company,s stock which is currently listed on the OTC ... Wexler, Company Chairman and CEO, "We are seeing an ... difficult to understand, not only by the Company, but ...
(Date:6/24/2016)... , June 24, 2016  Global Blood ... biopharmaceutical company developing novel therapeutics for the treatment ... today announced the closing of its previously announced ... stock, at the public offering price of $18.75 ... offering were offered by GBT. GBT estimates net ...
(Date:6/24/2016)... 2016 The Academy of Managed Care Pharmacy ... that would allow biopharmaceutical companies to more easily share ... formulary and coverage decisions, a move that addresses the ... The recommendations address restrictions in the sharing ... drug label, a prohibition that hinders decision makers from ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily ... of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures ... . Simply select a ProHand generator and drag it above media or text in ...
(Date:6/25/2016)... ... 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s a ... the bar too high can result in disappointment, perhaps even self-loathing. However, those who ... , Research from reveals that behind the tendency to set ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Scientific Sessions in Dallas that it will receive two significant new grants to ... came as PHA marked its 25th anniversary by recognizing patients, medical professionals and ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their ... Award, an essay contest in which patients and their families pay tribute to a ... the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
(Date:6/24/2016)... , ... June 24, 2016 , ... National recruitment firm ... life sciences executive with extensive sequencing and genomics experience, as Vice President of North ... Ms. Hill will be responsible for leading the sales team in the commercialization of ...
Breaking Medicine News(10 mins):